team of
professionals:
this is KIneto lab
Our mission is to enhance the quality of drug discovery and developmental concept of our partners using scientifically founded strategies and provide high quality services, in order to reach the clinical stage faster and with higher reliability
we are committed to
innovation and excellence
the whole process of drug development from target identification and validation through high throughput in vitro screenings to in vivo animal model studies
wide range of preclinical models, originated from human (xenograft) or murine (allo-/iso-graft) tumor cell lines, for testing various anticancer strategies and treatments
History
15 years of experience in cancer research.
KINETO Lab is a privately owned biotechnology research and CRO company based in Budapest, Hungary.
15 years of experience in cancer research. KINETO Lab is a privately owned biotechnology research and CRO company based in Budapest, Hungary.
company Establishment
Two of founders, Attila Kigyós and József Tóvári are the owners and are working for the company
20
07
“Magicbullet” consortium
KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie Actions “Magicbullet” consortium
20
15
endothelial markers
Tumor endothelial cell
research launched
20
17
PDTX biobank
First PDTX models established, PDTX biobank launched
20
19
NEW KRAS CONSORTIUM
The Company joined the Hungarian new KRAS consortium
20
21
NEW PROJECT
Coming soon
20
23
20
10
CD34 antibody
First own CD34 antibody developed
20
16
KRAS consortium
The Company joined the Hungarian KRAS consortium (RASopathies)
20
18
“Magicbullet::Reloaded”
KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie Actions “Magicbullet::Reloaded” consortium
20
20
related PhD work
Our work on endothelial cells reinforced by the company’s first related PhD research
20
22
NEXGEN CONSORTIUM
KINETO Lab Ltd. participating in HORIZON-HLTH to develop the Next generation vaccine platform for the treatment of Parkinson’s disease
company Establishment
Two of founders, Attila Kigyós and József Tóvári are the owners and are working for the company
20
07
CD34 antibody
First own CD34 antibody developed
20
10
“Magicbullet” consortium
KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie Actions “Magicbullet” consortium
20
15
KRAS consortium
The Company joined the Hungarian KRAS consortium (RASopathies)
20
16
endothelial markers
Tumor endothelial cell
research launched
20
17
“Magicbullet: :Reloaded”
KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie Actions “Magicbullet::Reloaded” consortium
20
18
PDTX biobank
First PDTX models established, PDTX biobank launched
20
19
related PhD work
Our work on endothelial cells reinforced by the company’s first related PhD research
20
20
NEW KRAS CONSORTIUM
The Company joined the Hungarian new KRAS consortium
20
21
NEXGEN CONSORTIUM
KINETO Lab Ltd. participating in HORIZON-HLTH to develop the Next generation vaccine platform for the treatment of Parkinson’s disease
20
22
NEW PROJECT
Coming soon
20
23
MANAGEMENT
Acknowledged experts providing tailored approaches for successful and effective research and development. Giving in our hands your concept guarantee you high quality investigation.
Attila Kigyós
founder and CEO KINETO Lab
«Drug development today requires effective collaboration between different disciplines. I consider it very important that our company excels in coordinating the work of chemists, biologists and statisticians. Therefore, I can confidently recommend our services to chemical researchers developing drugs, not only in the testing of their drug candidates, but also in the planning phase of the project.»
trust.
efficiency.
knowledge.
Attila Kigyós
MSc, Chief Executive Officer
József Tóvári
PhD, Chief Scientific Officer
Mihály Cserepes
PhD, Project Manager
Ivan Ranđelović
PhD, Project Manager
Attila Kigyós
MSc, Chief Executive Officer
Attila Kigyós, MSc, is the founder and CEO of KINETO Lab Research and Development Ltd. In addition to his role as Managing Director of the company, Attila has more than two decades of experience in the fields of informatics, biotechnology and drug discovery screening.
Attila was appointed for CEO based on his leadership experience in managing Hungarian biotech companies and his strong leadership and personal qualities.
József Tóvári
PhD, Chief Scientific Officer
József Tóvári, PhD, is the founder and CSO of KINETO Lab Research and Development Ltd., head of the Department of Experimental Pharmacology, National Institute of Oncology, Budapest.
Dr. Tóvari has a strong scientific experience in the field of translational applied research and development in oncology. He is co-author of 120 scientific publications; his cumulative impact factor is >500. He has >2800 independent citations.
Mihály Cserepes
PhD, Project Manager
Mihály is a postdoctoral biologist researcher and project manager in KINETO Lab, focusing his work on Patient-derived xenograft models, primary tumor cell line establishment and antibody development, as well as in vivo experiment planning and supervision.
Mihály is author of 13 peer-reviewed articles, with the total impact factor of 82.2, and 247 citations (as of February, 2023). He attended to more than 15 scientific conferences, earning two prizes for best poster.
Ivan Ranđelović
PhD, Project Manager
Ivan Ranđelović , PhD, is postdoctoral biologist researcher and project manager in KINETO Lab, focusing on drug discovery and preclinical investigation and development of targeting cancer therapeutics. Ivan is also responsible for the marketing and international relations of the company.
Ivan is author of 16 articles published in international peer-reviewed journals with a total impact factor of 64.1 which independently were cited over 100 times. He represented his work on numerous scientific conferences, where earned one prize for the best poster.
trust.
efficiency.
knowledge.
Attila Kigyós
Chief Executive Officer
Attila Kigyós, MSc, is the founder and CEO of KINETO Lab Research and Development Ltd. In addition to his role as Managing Director of the company, Attila has more than two decades of experience in the fields of informatics, biotechnology and drug discovery screening.
Attila was appointed for CEO based on his leadership experience in managing Hungarian biotech companies and his strong leadership and personal qualities.
József Tóvári
Chief Scientific Officer
József Tóvári, PhD, is the founder and CSO of KINETO Lab Research and Development Ltd., head of the Department of Experimental Pharmacology, National Institute of Oncology, Budapest.
Dr. Tóvari has a strong scientific experience in the field of translational applied research and development in oncology. He is co-author of 120 scientific publications; his cumulative impact factor is >500. He has >2800 independent citations.
Mihály Cserepes
PhD, Project Manager
Mihály is a postdoctoral biologist researcher and project manager in KINETO Lab, focusing his work on Patient-derived xenograft models, primary tumor cell line establishment and antibody development, as well as in vivo experiment planning and supervision.
Mihály is author of 13 peer-reviewed articles, with the total impact factor of 82.2, and 247 citations (as of February, 2023). He attended to more than 15 scientific conferences, earning two prizes for best poster.
Ivan Ranđelović
PhD, Project Manager
Ivan Ranđelović, PhD, is postdoctoral biologist researcher and project manager in KINETO Lab, focusing on drug discovery and preclinical investigation and development of targeting cancer therapeutics. Ivan is also responsible for the marketing and international relations of the company.
Ivan is author of 16 articles published in international peer-reviewed journals with a total impact factor of 64.1 which independently were cited over 100 times. He represented his work on numerous scientific conferences, where earned one prize for the best poster.
publications
KRAS targeting
Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency.
Orgován Z, Péczka N, Petri L, Ábrányi-Balogh P, Ranđelović I, Tóth S, Szakács G, Nyíri K, Vértessy B, Pálfy G, Vida I, Perczel A, Tóvári J and Keserű GM. Eur J Med Chem. 2023, 115212.
PDTX MODEL
Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets.
Tóvári J, Vári-Mező D, Surguta SE, Ladányi A, Kigyós A, Cserepes M.
Cells. 2023, 12(14), 1919.
PARKINSON’S DISEASE VACCINE
A Novel C-Type Lectin Receptor-Targeted α-Synuclein-Based Parkinson Vaccine Induces Potent Immune Responses and Therapeutic Efficacy in Mice.
Schmidhuber S, Scheiblhofer S, Weiss R, Cserepes M, Tóvári J, Gadermaier G, Bezard E, De Giorgi F, Ichas F, Strunk D, Mandler M. Vaccines (Basel). 2022 Aug 30; 10(9): 1432.
we Develop PDTX models resembling tumor heterogeneity and tumor microenvironment for better predictability of clinical therapeutic response
FACILITIES
We have licensed laboratory fully equipped with instruments for in vitro cell-based analysis and for molecular biology techniques, histochemical and patological studies. As well there is animal house for conducting animal experiments, with all official and ethical approvals.
technology
for histochemical & pathological studies
SPF
animal house
IVIS
in vivo imaging system
EQUIPPED
for cell culturing & molecular biology studies
03/08/2023
Lecture at International Conference on “Drug Conjugates for Directed Therapy”, from August 23rd to 25th, 2023, at Technical University of Darmstadt, Darmstadt, Germany
27/07/2023
Announce of the first publication using our Patient-Derived Tumor Xenograft (PDTX) models in Cells journal
13/07/2023
Publication in Frontiers in Pharmacology on Optimizing the Enzymatic Release of MMAE from isoDGR-based SMDC by Incorporation of a GPLG-PABC Enzymatically Cleavable Linker
CONTACTS
If you have any question regarding our research, services or PDTX models, and if you want to get in touch with us, fill the form or send us an e-mail on info@kinetolab.hu.
We are always open for your CV and application in case you would like to work in an innovative, dynamically growing cancer research-related biotech company in the future. If you think you could fit in KINETO Lab’s team, please contact us.